A multicenter, randomized, controlled clinical trial of efficacy and safety of xinan Guben Peiyuan formula series in the treatment of COPD

The First Affiliated Hospital of Anhui University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•? Patients who meet the diagnostic criteria for COPD; ? It belongs to stable period; ? It conforms to the TCM syndrome differentiation standard of lung qi deficiency/Lung spleen qi deficiency/lung kidney qi deficiency; ?40 years = age =75 years; ? Did not participate in other clinical studies 3 month before enrollment; ? No antibiotics were used 3 month before enrollment; ? Voluntarily accept treatment, sign informed consent before the test, and fully understand the content, process and possible adverse reactions of the test.

•If the answer to any of the following questions is yes, the patient will not be admitted to the study: ? Allergic constitution or allergic to the known ingredients of the test drug or control drug; ? Extremely severe COPD patients and acute stage patients; ? Pregnant and lactation women; ? Delirious, dementia, all kinds of mental patients; ? Functional grade ? and hemodynamic instability; ? With bronchiectasis, bronchial asthma, active pulmonary tuberculosis, pulmonary embolism, pneumothorax, pleural effusion, malignant tumor and other neuromuscular diseases affecting respiratory motor function;? Severe liver and kidney disease (severe liver disease refers to cirrhosis, portal hypertension and varicose bleeding, serious kidney disease including dialysis, kidney transplantation); ? all kinds of reasons for long-term bed. ? Persons who have participated in other interventional clinical trials within the last 3 months; ? Participants considered unsuitable for the clinical trial by the investigator.

发起方

The First Affiliated Hospital of Anhui University of Chinese Medicine